TANAC(SZ:300461)2019-10-28 16:00Financial Performance - Operating revenue for the reporting period was CNY 112,853,798.52, a decrease of 68.95% year-on-year[8]. - Net profit attributable to shareholders was CNY 10,408,925.90, down 83.36% year-on-year[8]. - Basic earnings per share decreased by 84.91% to CNY 0.08[8]. - The weighted average return on net assets was 5.14%, a decrease of 64.75% compared to the same period last year[8]. - Cash flow from operating activities decreased by 78.02% to CNY 17,952,734.49 year-to-date[8]. - Total operating revenue for Q3 2019 was CNY 112,853,798.52, a decrease of 68.9% compared to CNY 363,472,763.11 in the same period last year[61]. - The company's net loss for the period was CNY 8,483,380.31, indicating a significant decline in profitability compared to previous periods[61]. - Total operating revenue for the period was 228,687,527.96 CNY, down from 445,599,978.56 CNY year-over-year, representing a decrease of approximately 48.7%[74]. - Operating profit (loss) was -63,810,783.10 CNY, compared to a profit of 86,948,893.47 CNY in the previous year, reflecting a substantial downturn[74]. - The total comprehensive income attributable to the parent company was -84,995,808.68 CNY, compared to 86,015,604.78 CNY in the same period last year[71]. Asset and Liability Changes - Total assets decreased by 13.53% to CNY 1,206,007,451.36 compared to the end of the previous year[8]. - Total liabilities increased significantly, with other payables rising by 129.40% to ¥161,699,704.56 due to increased borrowings[16]. - The company's total equity decreased to CNY 227,229,289.95 from CNY 341,149,506.15, a decline of 33.4%[55]. - The total assets decreased to CNY 752,753,936.16 from CNY 808,465,749.67, a decline of 6.9%[58]. - Total liabilities amounted to CNY 1,023,444,883.83, indicating a stable financial position[86]. - The total liabilities were CNY 606,995,051.66, with current liabilities at CNY 492,720,983.04 and non-current liabilities at CNY 114,274,068.62[91]. Cash Flow and Financing Activities - Cash inflow from operating activities totaled 362,053,484.00 CNY, down from 585,470,465.45 CNY, indicating a decline in cash generation capabilities[77]. - Cash outflow from investing activities totaled CNY 47,561,197.12, down 69.7% from CNY 156,499,953.92 in the previous period[81]. - Cash inflow from financing activities was CNY 283,553,637.32, an increase of 20.9% compared to CNY 234,519,053.49 in the previous period[82]. - Net cash flow from financing activities was CNY 10,298,600.01, a significant decrease of 87.7% from CNY 83,990,402.00 in the previous period[82]. Legal Issues and Litigation - The company is currently involved in 28 ongoing lawsuits, which may impact future financial performance[17]. - The ongoing legal disputes may affect Yuan Yang Xiang Rui's operational capabilities and financial stability in the near term[30]. - Yuan Yang Xiang Rui has had its bank accounts frozen due to ongoing litigation, impacting its liquidity[26]. - The company is actively seeking resolutions to its legal issues to mitigate potential financial impacts[29]. - The total amount claimed in lawsuits against the company is substantial, indicating potential liquidity issues[32][33][34][35][36][37]. Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 6,220[12]. - The top ten shareholders held a combined 64.77% of the shares, with the largest shareholder holding 17.53%[12]. - The company completed the transfer of 9,867,526 shares at a price of RMB 20.00 per share on September 3, 2019, reducing the total share capital from 124,595,028 shares to 121,642,380 shares[42]. - The company plans to sell its 55% stake in Yuanyang Xiangrui Machinery Co., Ltd., as per the agreement signed on October 22, 2019[42]. Impairment and Expenses - The company recorded an asset impairment loss of ¥158,611,091.20, a 333.63% increase compared to the previous period[16]. - The company reported an asset impairment loss of CNY 18,519,885.20 for the current period[63]. - The company incurred research and development expenses of CNY 6,666,678.59, down from CNY 15,394,675.65, a decline of 56.6% compared to the previous year[66].